Palvella Therapeutics (PVLA) Competitors $36.55 -0.03 (-0.08%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock PVLA vs. IMCR, TARS, ADPT, SRPT, SDGR, EVO, EWTX, JANX, ABCL, and ANIPShould you be buying Palvella Therapeutics stock or one of its competitors? The main competitors of Palvella Therapeutics include Immunocore (IMCR), Tarsus Pharmaceuticals (TARS), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), Schrodinger (SDGR), Evotec (EVO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), AbCellera Biologics (ABCL), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Palvella Therapeutics vs. Its Competitors Immunocore Tarsus Pharmaceuticals Adaptive Biotechnologies Sarepta Therapeutics Schrodinger Evotec Edgewise Therapeutics Janux Therapeutics AbCellera Biologics ANI Pharmaceuticals Palvella Therapeutics (NASDAQ:PVLA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment. Do insiders & institutionals hold more shares of PVLA or IMCR? 40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 20.5% of Palvella Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate PVLA or IMCR? Palvella Therapeutics presently has a consensus target price of $47.50, suggesting a potential upside of 29.96%. Immunocore has a consensus target price of $58.89, suggesting a potential upside of 78.51%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Immunocore 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55 Which has stronger valuation & earnings, PVLA or IMCR? Palvella Therapeutics has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M9.44-$17.43M-$12.10-3.02Immunocore$310.20M5.34-$51.09M-$0.43-76.72 Which has more risk & volatility, PVLA or IMCR? Palvella Therapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Is PVLA or IMCR more profitable? Palvella Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.48%. Immunocore's return on equity of -5.86% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -60.29% -43.30% Immunocore -6.48%-5.86%-2.09% Does the media favor PVLA or IMCR? In the previous week, Immunocore had 2 more articles in the media than Palvella Therapeutics. MarketBeat recorded 4 mentions for Immunocore and 2 mentions for Palvella Therapeutics. Palvella Therapeutics' average media sentiment score of 1.53 beat Immunocore's score of 0.87 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPalvella Therapeutics beats Immunocore on 9 of the 17 factors compared between the two stocks. Get Palvella Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PVLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PVLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PVLA vs. The Competition Export to ExcelMetricPalvella TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$404.42M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-3.0217.6228.6723.80Price / Sales9.44179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book6.558.508.275.55Net Income-$17.43M-$55.06M$3.24B$259.03M7 Day Performance-5.36%-3.98%-3.69%-4.59%1 Month Performance53.38%9.59%4.33%4.46%1 Year PerformanceN/A6.72%25.95%18.03% Palvella Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PVLAPalvella Therapeutics2.6822 of 5 stars$36.55-0.1%$47.50+30.0%N/A$404.42M$42.81M-3.02N/AIMCRImmunocore1.7245 of 5 stars$33.50-1.2%$58.89+75.8%-16.7%$1.70B$310.20M-77.91320News CoverageUpcoming EarningsTARSTarsus Pharmaceuticals2.5288 of 5 stars$40.00-0.3%$66.67+66.7%+74.2%$1.69B$182.95M-14.6550Positive NewsUpcoming EarningsADPTAdaptive Biotechnologies3.0058 of 5 stars$10.44+0.5%$10.57+1.3%+132.1%$1.58B$178.96M-10.88790Positive NewsUpcoming EarningsGap DownSRPTSarepta Therapeutics4.71 of 5 stars$16.75+5.8%$49.12+193.3%-89.0%$1.56B$1.90B-6.231,372Trending NewsUpcoming EarningsAnalyst ForecastOptions VolumeHigh Trading VolumeSDGRSchrodinger2.5882 of 5 stars$20.71-2.2%$32.75+58.1%-13.6%$1.55B$207.54M-7.87790Positive NewsUpcoming EarningsGap DownEVOEvotec2.0865 of 5 stars$4.17-1.7%$5.90+41.5%-13.2%$1.51B$862.40M0.004,827News CoverageEWTXEdgewise Therapeutics2.2917 of 5 stars$14.23+2.0%$40.55+184.9%-14.6%$1.47BN/A-9.1860News CoverageUpcoming EarningsAnalyst ForecastJANXJanux Therapeutics2.4087 of 5 stars$24.23+0.2%$91.89+279.2%-43.2%$1.43B$10.59M-17.8230Positive NewsUpcoming EarningsGap UpABCLAbCellera Biologics2.4221 of 5 stars$4.57-2.6%$8.75+91.5%+39.0%$1.40B$28.83M-8.16500News CoverageUpcoming EarningsANIPANI Pharmaceuticals3.7646 of 5 stars$64.03-0.3%$78.88+23.2%+0.1%$1.39B$614.38M-50.42600Upcoming Earnings Related Companies and Tools Related Companies IMCR Competitors TARS Competitors ADPT Competitors SRPT Competitors SDGR Competitors EVO Competitors EWTX Competitors JANX Competitors ABCL Competitors ANIP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PVLA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVLA Stock Alerts